Biogen Inc. Announces Topline Results from Tofersen Phase 3 Study and Its Open Label Extension in Sod1-Als to Be Presented At the American Neurological Association Annual Meeting

Biogen Inc. announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021.